IFN-g production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo
In PLoS ONE, 2004
... anti-CD123 (9F5, BD Biosciences), anti-CD127 (HIL-7R-M21, BD Pharmingen), anti-CD303 (AC144, Miltenyi Biotec), anti-Foxp3 (259D, eBioscience), anti-CTLA-4 (BNI3, BD Biosciences).
The immune system and cancer evasion strategies: therapeutic concepts.
Basel, Switzerland. In J Intern Med, Feb 2016
Finally, we will focus on therapies that are already used in daily oncological practice such as the blockade of immune checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) in patients with metastatic melanoma or advanced lung cancer, or therapies currently being tested in clinical trials such as adoptive T-cell transfer.
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Sacramento, United States. In Ther Adv Med Oncol, Jan 2016
The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013.
Cellular immune responses towards regulatory cells.
In Dan Med J, Jan 2016
This is being done through immune checkpoint blockade with CTLA-4 and PD-1/PD-L1 antibodies and through lymphodepleting conditioning of patients and ex vivo activation of TILs in adoptive cell transfer.
Genomics of Immune Diseases and New Therapies.
Bethesda, United States. In Annu Rev Immunol, Jan 2016
At the end, we discuss two other recently described diseases, PASLI (PI3K dysregulation) and CHAI/LATAIE (CTLA-4 deficiency), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.
Updates in Therapy for Advanced Melanoma.
Durham, United States. In Cancers (basel), Dec 2015
The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Boston, United States. In Science, Nov 2015
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized.
Releasing the Brakes on Cancer Immunotherapy.
New York City, United States. In Cell, Oct 2015
This year's Lasker∼DeBakey Clinical Research Award goes to James Allison for discovering that antibody blockade of the T cell molecule CTLA-4 unleashes the body's immune response against malignant tumors.